Psychiatry Investigation
October 10, 2021
Chia‐ling Yu, Fu-Chi Yang, Szu‐nian Yang et al.
57 citations
A meta-analysis of five clinical trials found that psilocybin is superior to placebo for reducing end-of-life anxiety symptoms. Psilocybin reduced state anxiety at 1 day and 2 weeks after treatment, and trait anxiety at 1 day, 2 weeks, and 6 months after treatment. Psilocybin caused a temporary increase in systolic and diastolic blood pressure compared with placebo. There were no significant differences between psilocybin and placebo in rates of stopping treatment, serious adverse events, or heart rate. The authors conclude that psilocybin-assisted therapy can improve end-of-life anxiety without serious side effects, but note the small sample sizes and high heterogeneity in long-term outcomes.
Journal of Clinical Medicine
February 11, 2022
Chia‐ling Yu, Chih-Sung Liang, Fu-Chi Yang et al.
37 citations
A meta-analysis of ten studies found that one or two doses of psilocybin produce rapid and sustained antidepressant effects lasting up to six months. Depressive symptoms decreased substantially, with the largest effect at one week (standardized mean difference -1.74) and a still-large effect at six months (-1.12). Higher doses and two sessions were linked to greater improvement. Psilocybin raised systolic blood pressure by 19.00 mmHg and diastolic by 8.66 mmHg, but discontinuation rates and heart rate changes were similar to placebo. The findings suggest psilocybin has favorable cardiovascular safety and acceptability for treating depression.
Mindfulness
May 17, 2025
Michel Sabé, Chaomei Chen, Davy Vancampfort et al.
7 citations
A scientometric analysis of 16,310 documents from 1973 to 2023 reveals that mindfulness dominates mind–body intervention research, but each practice—Yoga, Qi-gong, Tai-chi, Vipassana, Zen, Loving-kindness, and Transcendental meditation—has distinct research clusters focused on different mental and physical health issues, such as substance abuse, schizophrenia, back pain, and dementia. The findings suggest that future research should recognize the unique contributions of each practice rather than treating them as a single category.
Discover Mental Health
March 7, 2026
Nicholas Fabiano, Brendon Stubbs, David W. Lawrence et al.
More than half of people with major depressive disorder do not respond to standard treatments, prompting interest in alternatives such as exercise and psychedelics. This commentary examines how these two approaches might work together. Biologically, psychedelics briefly boost brain-derived neurotrophic factor (BDNF) signaling, while exercise provides sustained BDNF elevation; psychedelics enhance neuroplasticity mainly in the cortex, whereas exercise promotes hippocampal neurogenesis; both increase serotonin release. Psychologically, psychedelics may help people adopt exercise habits, and exercise may improve emotional resilience, potentially deepening the psychedelic experience. The authors suggest that these complementary mechanisms warrant future research on their combined efficacy, tolerability, safety, and neurobiology.
Journal of Psychiatric Research
February 1, 2021
Davy Vancampfort, Brendon Stubbs, Tine Van Damme et al.
A systematic metareview of 17 meta-analyses found that meditation-based mind-body interventions, particularly mindfulness and yoga, can be effective supplements for mental disorders. Among meta-analyses with good methodological quality and content validity, large effect sizes were observed for mindfulness in schizophrenia and ADHD, a moderate effect size for mindfulness in PTSD, and a small effect size for yoga in schizophrenia. No serious adverse events were reported across 43 randomized controlled trials involving 1,774 participants in the mind-body intervention arms, and attrition rates were comparable to control conditions. The authors conclude that mindfulness and yoga may serve as efficacious supplements to pharmacotherapy and psychotherapy, while evidence for qigong and tai chi remains lacking.